An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
July 20th, 2014
There is a discernible need for improved information on molecular drivers of Barrett’s Esophagus. Immunofluorescent staining is a useful technique for understanding the effects of cell signaling on cell morphology. We present a simple, effective protocol for the use of immunofluorescent staining to assess therapeutic treatment in Barrett’s Esophagus cells.
The overall goal of the following experiment is to assess the effects of drug treatment upon cell structure and protein localization in BE cells. This is achieved by incubating the BE cells grown onto the glass cover slips with a chosen drug in standard cell culture conditions. As a second step incubate the treated be cells with a fixative, which preserves protein structure and localization.
Next fixed be cells are incubated sequentially with primary and fluorescently tagged secondary antibodies in order to visualize changes in the selected target protein via fluorescence microscopy results are obtained that show how drug treatment of be cells alters protein localization and cell structure based on visualization of immunofluorescent staining. Though this method can provide insight into Barrett's esophagus, it can also be applied to other systems including cancer and normal cells. Begin this procedure by placing the 18 millimeter cover slips in a glass Petri dish and autoclave them.
Then transfer the autoclave cover slips to a 12 well tissue culture dish using a sterile glass pipette attached to a vacuum tube. After that wash, the cover slips with sterile PBS and media. Next trypsin.
The immortalized cells count the cells using an automated cell counter or a hemo cytometer subsequently dilute the cells in culture media to a concentration of 20, 000 to 40, 000 cells per milliliter. Then place one milliliter of cells into each well containing a cover slip. For a total cell count of 20, 000 to 40, 000 cells per well use a sterile pipette tip to gently push the cover slip to the bottom of the well to ensure that the cells attach to the cover slip.
To treat the BE cells, dilute the selected drug in 37 degrees Celsius Media to the desired concentration mix well by inverting the tube repeatedly or using a vortex mixer. Begin treatment 24 hours following the initial seating of the BE cells to allow for cell attachment onto the cover Slip now pre-labeled drug and vehicle treated sample plates with a lab pen to distinguish between comparison and control. Treat an additional cover slip of be cells with 0.1%vehicle diluted in the culture media.
Afterward, place the cells in a cell culture incubator at 37 degrees Celsius, 5%carbon dioxide and 98%humidity. Now after the desired incubation time of drug treatment, aspirate the media and wash the cover slips quickly with one XPBS at room temperature. Then aspirate the PBS and add one milliliter of PBS containing 4%PFA to each well and incubate at room temperature for 30 minutes.
Next, aspirate the 4%P-F-A-P-B-S Wash the cover slips three times five minutes each time with PBS at room temperature. Store the cover slips for one week in PBS and 0.1%PFA at four degrees Celsius if desired. To permeable eyes the fixed PFA cells in order to allow the antibody to access the intracellular targets, incubate the cells with 50 millimolar ammonium chloride diluted in PBS for 10 minutes at room temperature.
Then wash them with room temperature PBS once for five minutes. This will reduce the background to prevent non-specific binding of antibodies to the cellular proteins. Incubate the BE cells for 30 minutes in 100 to 300 microliters of PBS containing 0.1%troponin and 0.5%BSA.
Then prepare a square bioassay dish by layering the bottom of the chamber with wet paper towels and placing a layer of parfum on top. Mark the Parfum with a lab pen to identify the cover slips. Gently transfer the cover slips cells facing upward onto the param using forceps and a syringe needle.
Now dilute the primary antibody in PBS containing both 0.5%BSA and 0.1%saponin gently blot off the blocking solution. Using a laboratory tissue, add 100 microliters of the primary antibody solution and incubate the be cells overnight at four degrees Celsius. The next day.
Wash the slides three times with PBS containing 0.5%BSA and 0.1%troponin for five minutes each time at room temperature. Then dilute the secondary antibody conjugated with a fluorescent tag in PBS containing 0.5%BSA and 0.1%ponent. Add 100 microliters of diluted antibody to each cover slip and incubate the cells for two hours at room temperature After two hours.
Wash the cover slips three times five minutes each time in PBS containing 0.5%BSA and 0.1%troponin. Remove the wash buffer and add 100 to 300 microliters of PBS to the cover slips. Gently lift up the cover slip with forceps and blot off the PBS using a laboratory tissue or paper towel.
Then add 15 microliters of a suitable Antifa mounting media containing DPI to the cover slip. Place the inverted cover slip onto a glass microscope slide with the cells facing down. Subsequently place the slides into a slide folder and keep them away from direct light overnight at room temperature to allow the Antifa medium to cure.
Once the Antifa medium has set, the slides can be stored at either four degrees Celsius or negative 20 degrees Celsius until microscopic visualization. In this step, remove the storage slides from negative 20 degrees Celsius or four degrees Celsius and allow them to warm to room temperature. Turn on the microscope and the mercury arc lamp.
Place a microscope slide with the cover slip facing towards the objective onto the microscope stage. Next, select the DAPI filter and open the shutter. Focus the objective while looking through the eye pieces until the image appears.
Since all cells have been stained with dpi, the nuclei should be easily observed. Collect images using appropriate image processing software in this figure cover slips with CPC and CPD were treated with vehicle or one micromolar of the SRC inhibitor. SKI 6 0 6 for 24 hours be cells were then fixed and stained.
According to the described protocol, beta catenin indicated in green was visualized using a specific antibody and a secondary antibody coupled to LOR 4 88 while the nucleus was stained with DPI indicated in blue. Note the change in location of beta-catenin from the nucleus to the cell membrane. Following treatment with SKI 6 0 6.
After watching this video, you should have a good understanding of how to immuno fluorescently stain Barrett's esophagus to investigate protein localization or cell structure.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for immunofluorescent staining to study Barrett's Esophagus cells. The method allows researchers to assess the effects of drug treatment on cell structure and protein localization.
Key Study Components
Area of Science
- Cell Biology
- Neuroscience
- Oncology
Background
- Barrett's Esophagus is a condition that requires better understanding of its molecular drivers.
- Immunofluorescent staining is a valuable technique for visualizing cellular changes.
- Drug treatment can alter protein localization and cell morphology.
- This method can also be applied to other cell types, including cancer cells.
Purpose of Study
- To evaluate the impact of drug treatment on Barrett's Esophagus cells.
- To visualize changes in protein localization using fluorescence microscopy.
- To provide a straightforward protocol for researchers in the field.
Methods Used
- Incubation of BE cells with a drug under standard culture conditions.
- Fixation of treated cells to preserve protein structure.
- Sequential incubation with primary and fluorescently tagged secondary antibodies.
- Visualization of protein localization changes via fluorescence microscopy.
Main Results
- Drug treatment resulted in observable changes in protein localization.
- Cell structure alterations were documented through immunofluorescent staining.
- The method proved effective for assessing therapeutic interventions.
- Insights gained can be applied to other biological systems.
Conclusions
- The protocol is a valuable tool for studying Barrett's Esophagus.
- Immunofluorescent staining can enhance understanding of cellular responses to treatment.
- Further applications in cancer research are possible.
Frequently Asked Questions
Executive Industry Relevance
This immunofluorescent staining method enables biopharma R&D teams to assess drug-induced changes in protein localization and cell structure in Barrett's esophagus models, supporting target validation and mechanistic de-risking in esophageal adenocarcinoma drug discovery. By providing a reproducible, quantitative readout of therapeutic compound effects on signaling pathways, the technique enhances predictive confidence in preclinical screening and portfolio triage decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing drug-induced alterations in key signaling proteins such as beta-catenin.
- Operational Value: Provides a standardized, microscopy-based assay for functional target validation in immortalized Barrett's esophagus cell lines.
- Strategic Value: Supports biological de-risking and predictive confidence in target selection by linking compound treatment to observable subcellular reorganization.
Screening & Assay Development
- Scientific Value: Generates quantitative fluorescence readouts that enable compound screening for modulators of protein localization and cellular architecture.
- Operational Value: Establishes a reproducible, standardized immunofluorescent workflow compatible with multi-well plate formats and automated imaging systems.
- Strategic Value: Facilitates assay scalability and cross-platform reuse for lead identification campaigns targeting esophageal adenocarcinoma pathways.
Translational & Preclinical Research
- Scientific Value: Maintains disease relevance by modeling Barrett's esophagus-to-adenocarcinoma progression mechanisms in vitro.
- Operational Value: Ensures translational continuity from discovery through preclinical validation via consistent protein localization readouts.
- Strategic Value: Informs risk-adjusted advancement decisions by providing mechanistic insights into compound effects on epithelial-mesenchymal transition and tumorigenic pathways.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through lead identification to preclinical mechanistic studies, enabling iterative assessment of compound effects on Barrett's esophagus cell biology.
- Discovery Biology: Supports hypothesis testing and pathway clarification by visualizing drug-induced shifts in oncogenic signaling proteins.
- Screening: Delivers assay readiness and quantitative outputs for evaluating compound libraries against Barrett's esophagus-relevant targets.
- Analytics: Generates fluorescence-based measurements and localization metrics that enable side-by-side comparison of treatment conditions.
- Translational Research: Connects discovery findings to preclinical continuity by modeling human disease-relevant cellular responses to therapeutic intervention.
- Enterprise Reuse: Functions as a reusable imaging platform applicable across cancer and normal cell systems for broad target validation efforts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through direct visualization of protein localization changes.
- Operational Value: Enhances standardization, reproducibility, and scalability of cellular imaging assays across discovery and preclinical teams.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling early detection of biologically active compounds.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement decisions by linking phenotypic screening results to mechanistic pathways in esophageal adenocarcinoma.
Implementation Considerations
- Requires expertise in cell culture, immunofluorescence microscopy, and antibody-based detection techniques.
- Dependent on access to fluorescence microscopy systems, glass cover slips, and standardized reagent kits for fixation and permeabilization.
- Necessitates cross-team standardization of staining protocols, imaging settings, and analysis pipelines for reproducible results.
- Involves adaptation considerations when transferring the method to different cell models or extracellular matrix conditions.
- Limited by the availability of validated primary antibodies specific to targets of interest in Barrett's esophagus signaling pathways.
